Q-omics provides the consensus-scored PRSS45P profile across patient tissues and cancer cell-line models. PRSS45P expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PRSS45P is differentially expressed in 6, with the highest sampling consensus in LUAD. Additionally, PRSS45P RNA expression shows 15,279 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, LUAD, and UVM as cancer lineages where PRSS45P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRSS45P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRSS45P survival associations across molecular data types. PRSS45P RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRSS45P RNA expression–survival associations across cancer types. High PRSS45P expression shows unfavorable associations in COAD, but favorable associations in HNSC, UCS, PAAD, UCEC and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for PRSS45P RNA expression.
This table summarizes PRSS45P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for PRSS45P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRSS45P shows lower tumor expression in KIRC, BRCA, HNSC, PRAD and ESCA and higher tumor expression in LUAD. The LUAD box plot shows higher PRSS45P RNA expression in tumor versus normal tissue (log2 FC = +0.571, t-test p < 0.001).
This table shows molecular features associated with PRSS45P in patient tissues and cancer cell lines. In patient samples, PRSS45P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRSS45P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
